ACP-105
A partial androgen receptor agonist from a tricyclic scaffold, studied for dissociated tissue effects.
Non-steroidal SARM, tricyclic scaffold
AC-262536
AC-262,536, Accadine
A partial androgen receptor agonist investigated in preclinical models of muscle and central androgen signalling.
Research use only. This compound is supplied for laboratory
research and analytical use. It is not a medicine, not a supplement and
not for human or veterinary consumption. Prohibited in sport at all times under WADA Section S1.2.
Chemical identity
AC-262536 is the second compound on this site from the Acadia Pharmaceuticals SARM programme, sharing a research lineage with ACP-105 but a distinct structure. It is sometimes listed under the developmental name Accadine.
It is characterised as a partial agonist at the androgen receptor, with reported intrinsic activity below that of testosterone in the assays used during its characterisation.
Mechanism in research models
The binding and transcriptional mechanism is the standard androgen receptor pathway. What distinguishes the compound in its published characterisation is the reported separation between anabolic and androgenic endpoints in the castrated-rat model, where levator ani response substantially exceeded prostate and seminal vesicle response.
Partial agonism has a consequence that is easy to miss in experimental design: in a system with normal endogenous androgen present, a partial agonist competing for receptor occupancy can reduce net signalling. Whether the compound appears anabolic or antiandrogenic therefore depends on the hormonal status of the model.
Some published work has examined effects on androgen receptor expression in central nervous tissue, consistent with the receptor's known CNS distribution. These findings are preliminary.
What the literature establishes
The published dataset is thin — conference material and a limited set of rodent studies from the developmental period. This compound has less peer-reviewed characterisation than most items on this site.
No human data exist. Pharmacokinetic parameters, metabolism and clearance in any species other than rodents are unpublished.
Prohibited in sport under WADA S1.2. Included in screening panels and identified in analytical surveys of the grey supplement market.
Handling, storage and solubility
Storage and handling. Follow the approved conditions stated on the current lot-specific certificate of analysis and safety data sheet. The notes below describe general laboratory practice for this class of material and do not override the lot documentation. Contact research@apexscienceslabs.com before ordering if those documents are not available.
Material of this class is typically held sealed at −20 °C, protected from light and moisture, and is stable as a dry solid under those conditions; confirm the validated condition and the physical form on the lot documentation.
Insoluble in water. DMSO stock, aqueous dilution at point of use, vehicle-matched controls at the same final solvent concentration.
Because the published characterisation is limited, treat solubility and stability figures on any certificate as batch-specific claims to verify rather than established constants for the compound.
Analytical documentation
Require HPLC purity, NMR and mass spectrometry. For a compound with this little published characterisation, the analytical package is doing more work than usual — it is the primary evidence that the material is what the label says.
Ask the supplier for the reference standard or literature data against which identity was assigned. A certificate that confirms a structure without stating what it was compared against is not an identity confirmation.
References and authoritative sources
Chemical identity, regulatory status and anti-doping classification should be confirmed against primary sources rather than against this page. The records below are the ones to check first.
These are database and regulatory sources. Citations to specific primary papers are being added to this page as part of ongoing scientific review; until they appear, treat the mechanism and literature sections above as a summary to verify rather than a citation of record.
Editorial accountability
Written by Apex Sciences Labs editorial teamNot yet attributed to a named author
Scientific review Pending named reviewThis page has not yet been reviewed by a named, credentialled reviewer
Published August 26, 2026First publication of this page
Last reviewed September 22, 2026Identity, mechanism, literature limitations, handling statements and references.
Found an error? Report it to research@apexscienceslabs.com — see our corrections policy and editorial policy.
Next step
Enquire about AC-262536
Include the quantity and the intended laboratory application. We will respond with the current specification and the batch documentation available.